Roche’s Susvimo Gets EU Approval Recommendation for nAMD
Roche (OTCQX: RHHBY) announced that the EMA’s Committee for Medicinal Products for Human Use (CHMP)…
CHMP recommends EU approval of Roche’s Susvimo, the first continuous delivery treatment for neovascular age-related macular degeneration (nAMD)
F. Hoffmann-La Roche Ltd Susvimo is the first and only continuous delivery treatment that offers an alternative to…
CHMP recommends EU approval of Roche’s Susvimo, the first continuous delivery treatment for neovascular age-related macular degeneration (nAMD)
F. Hoffmann-La Roche Ltd Susvimo is the first and only continuous delivery treatment that offers an alternative to…
CHMP recommends EU approval of Roche’s Susvimo, the first continuous delivery treatment for neovascular age-related macular degeneration (nAMD)
Susvimo is the first and only continuous delivery treatment that offers an alternative to standard of care eye…
Genentech brings 45 ophthalmology abstracts to ARVO 2026
04/30/2026 –…
Roche to present 45 ophthalmology studies at ARVO
Roche (OTCQX: RHHBY) will present more than 45 abstracts at ARVO 2026 (3–7…
Roche’s Contivue Earns CE Mark for Continuous Eye Disease Treatment
Roche (OTCQX:RHHBY) has received CE mark approval for Contivue, its Port Delivery Platform…